T1	Outcomes 0 10	Evaluation
T2	Outcomes 152 179	pharmacokinetic interaction
T3	Outcomes 378 405	pharmacodynamic interaction
T4	Outcomes 484 506	antiplatelet activity.
T5	Outcomes 816 886	aspirin reactivity units (ARU, as measured by the VerifyNow ASA assay)
T6	Outcomes 1193 1343	antiplatelet activity of ASA, as assessed by ARU ratio relative to baseline in the VerifyNow ASA assay; suppression of serum thromboxane B(2) (TXB(2))
T7	Outcomes 1597 1609	achieved ARU
T8	Outcomes 1668 1699	(baseline) platelet aggregation
T9	Outcomes 1830 1853	of platelet aggregation
T10	Outcomes 1953 1973	reduced serum TXB(2)
T11	Outcomes 2019 2041	of serum TXB(2) levels
T12	Outcomes 2141 2155	well tolerated
T13	Outcomes 2168 2198	No pharmacodynamic interaction
T14	Outcomes 2259 2279	to platelet function
